Precise Health Secures Early Funding to Advance Personalised Bacteriophage Therapies Against Antimicrobial Resistance
Precise Health, a Swiss biotech start‑up developing personalised bacteriophage therapies to combat antimicrobial resistance, has taken early steps in securing funding and support as it moves from concept toward validation and pilot programmes. Founded in 2023 and based in Sion, Switzerland, the company’s mission is to replace broad‑spectrum antibiotics with AI‑assisted, highly targeted phage treatments that attack only harmful bacteria while preserving beneficial microbiota — a solution aimed at addressing the global health crisis of antimicrobial resistance.
Since its inception, Precise Health has attracted support and seed capital from several innovation and accelerator programmes that are helping it bridge the early development gap typical for deep biotech ventures. One of the company’s first sources of backing came through the Venture Kick programme, a well‑known Swiss early‑stage support initiative that provides start‑ups with initial capital, mentoring and access to investor networks. Participation in Venture Kick typically includes staged grants — often starting at CHF 10,000 — and is designed to help founders formalise a business strategy and reach investor‑ready milestones.
In addition to support from Venture Kick, Precise Health has also been recognised in the City of Sion’s Innovation Programme, through which it obtained CHF 40,000 in funding. This municipal innovation initiative aims to stimulate local economic development by providing grants to high‑potential start‑ups that contribute technological advancement and job creation in the region. The funds from the City of Sion will help Precise Health accelerate clinical pilot studies and deepen strategic partnerships, enabling the company to refine its AI‑driven platform and move closer to real‑world testing scenarios.
Beyond financial support, Precise Health’s early recognition has included awards and accolades within the biotech ecosystem. The company won the Best Innovation Award at the 2025 Targeting Phage Therapy Congress in Berlin, signalling strong peer recognition of its approach to personalised antimicrobial therapy. This award highlighted Precise Health’s technological promise and helped raise its profile within the global phage therapy community.
While Precise Health has not yet announced a traditional venture funding round with institutional investors, its inclusion in accelerator and city‑level innovation programmes reflects early investor and ecosystem confidence. According to industry profiles, the company has raised a total of approximately $10,000 in formal funding rounds — a figure indicative of its very early stage rather than its long‑term capital needs — and is complemented by non‑dilutive support that is critical for advancing its biotechnology platform.
Precise Health’s technology combines genomics, machine learning and synthetic biology to rapidly identify and match bacteriophages — viruses that naturally infect and kill bacteria — to specific resistant infections. Its proprietary systems, including tools referred to on its corporate profiles as PhageMatch and PhageTailor, are designed to accelerate personalised treatment decision‑making in cases where traditional antibiotics are ineffective. By integrating data from global phage biobanks and leveraging AI to optimise matches, the platform aims to offer a more precise alternative to broad‑spectrum antibiotic therapy.
Antimicrobial resistance (AMR) is recognised as one of the most serious global health threats, with resistant infections causing significant mortality and economic burden annually. Precise Health’s ambition to personalise phage therapy is positioned as a direct response to this crisis, seeking not only to improve outcomes for patients with hard‑to‑treat infections but also to reduce reliance on traditional antibiotics that can disrupt healthy microbiomes and contribute to resistance development.
As the start‑up progresses, its immediate focus will be on completing further validation studies, expanding its strategic collaborations, and preparing for larger funding rounds that can support clinical advancement and regulatory engagement. The early backing from innovation support programmes and seed‑level funding provides a foundation on which Precise Health hopes to build momentum toward commercialisation and broader impact in global health.
